Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2023 16:05 ET | Source: Icosavax, Inc.

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update

- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...